Endocrine Cancer

Our findings indicate that DLL3 is frequently expressed in MTC and its high expression identifies tumors with aggressive pathological characteristics and poor clinical outcomes. These results support DLL3 as a potential prognostic biomarker and therapeutic target in MTC, highlighting the need for further validation and integration into clinical trials of DLL3-directed therapies.

P1/2, N=150, Recruiting, Crinetics Pharmaceuticals Inc. | Not yet recruiting --> Recruiting

The predominant presentation with non-specific abdominal pain significantly amplifies diagnostic complexity in such cases. This underscores the necessity for heightened clinical vigilance for NENs when evaluating atypical presentations.

This study establishes AFP elevation, mixed histology, and delayed chemotherapy as critical determinants of poor prognosis in GB-NEC. Our findings emphasize the importance of early diagnosis, aggressive surgical resection, and timely initiation of platinum-based adjuvant therapy.

P2, N=14, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=29 --> 14

P1, N=12, Not yet recruiting, Memorial Sloan Kettering Cancer Center | Initiation date: Oct 2025 --> Jan 2026

IGF-II-secreting tumours are widely associated with mesenchymal tumours; however, this case presents a rare possible association with bladder tumours. Surgical resection of NICTH tumours is the mainstay of treatment, but when it is not feasible, other medical management should be explored.

The results highlighted a small number of tumor entities that could be targeted by anti-L1CAM drugs, once these are proved to be sufficiently safe and efficient. L1CAM expression does not appear to confer an aggressive phenotype to affected cancer cells.

The patient received four cycles of adjuvant etoposide-cisplatin (EP) chemotherapy. We report a case managed with umbilicus-sparing urachectomy and extended partial cystectomy followed by EP chemotherapy, together with a review of nine previously published cases. These findings provide literature-based evidence to guide individualized management and inform future multidisciplinary research.

These findings demonstrate that high-coverage NGS of multiple tissues is critical for identifying low-level mosaic MEN1 mutations missed by standard testing. Alternative screening methods are required for patients with strong clinical indications of MEN-1 and/or a family history, but negative germline test results, one such method is NGS with high coverage.

Accordingly, the present case was diagnosed as a mucinous carcinoma (MC) of hypercellular type with neuroendocrine differentiation. To the best of our knowledge, a cystic MC of the breast exhibiting growth patterns of EPC has not been previously described.

This commentary emphasizes the pressing need for comprehensive diagnostics and further research to advance treatment strategies for this rare and challenging malignancy.